📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 16:22
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
Best Agrolife Q1 FY27: PAT Doubles to ₹41 Cr as Patented Product Mix Hits 65%
Best Agrolife reported a resilient Q1 FY27 with revenue growing 4% YoY to ₹396 Cr, despite delayed monsoons and El Niño concerns. The company achieved a significant margin expansion, with Gross Margins reaching 37% and PAT more than doubling to ₹41 Cr, driven by a strategic shift toward patented products. Management has proactively provided ₹60 Cr for potential sales returns to mitigate historical volatility in the second half of the year. While early season demand was subdued, recent rainfall improvements have led to a cautiously optimistic outlook for the Rabi season.
Confidence: HIGH
What changedThe company has successfully transitioned its portfolio toward high-margin patented products (65% mix), leading to a decoupling of profit growth from revenue growth.
Why it mattersThe shift to patented products provides higher pricing power and EBITDA margins (30-35% for patents vs 11-15% for total business), creating a buffer against raw material volatility and climate-induced revenue fluctuations.
Q1 Revenue: ₹396 CrQ1 PAT: ₹41 CrPatented Product Mix: 65%Sales Return Provision: ₹60 CrGross Margin: 37%Q1 Revenue vs TTM Revenue: 31.5%
📅 Short termThe stock may react positively to the sharp recovery in profitability and margin expansion, especially following the net loss reported in the March 2026 quarter.
📈 Long termThe structural shift toward a 'pull' model and a patented-heavy portfolio could stabilize earnings and reduce the impact of seasonal failures over the next 2-3 years.
⚠ Risk flags
- Climate risk (El Niño impact on Rabi season)
- Historical volatility in sales returns
- Working capital pressure from distributor credit cycles
Key Highlights
PAT more than doubled YoY to ₹41 Cr in Q1 FY27, up from ₹20 Cr in the same period last year.
Patented product contribution to branded sales increased significantly to 65% from 45% YoY.
EBITDA grew by 70% YoY with EBITDA margins reaching 20% due to favorable product mix.
A prudent provision of ₹60 Cr (approx 20% of expected returns) was made to buffer against future sales returns.
Gross margins expanded by 800 basis points to 37% from 29% in the previous year's quarter.
👀 What to Watch
Investors should monitor the actual realization of sales returns in Q3 and Q4 against the ₹60 Cr provision and track the recovery of reservoir levels in South India, which are currently at 81.5 billion cubic meters, to gauge Rabi season demand.
104% PAT Growth in Q1 FY27; EBITDA Margins Expand to 20% on Patented Product Mix
Best Agrolife reported a strong turnaround in Q1 FY27, with PAT doubling to ₹41 crore compared to ₹20 crore in Q1 FY26. Revenue grew 4% YoY to ₹396 crore, but more significantly, it surged 154% sequentially from a weak Q4 FY26. The growth was driven by a 37% volume increase in patented products, which now comprise 64% of branded sales. EBITDA margins expanded by 800 bps to 20%, reflecting a successful shift toward high-margin proprietary formulations despite uneven monsoon rainfall.
Confidence: HIGH
What changedThe company has successfully pivoted its sales mix toward patented products (64% of branded sales), leading to a significant recovery in profitability after a loss-making Q4 FY26.
Why it mattersThe agrochemical industry is currently facing pricing pressure in generics; Best Agrolife's focus on patented formulations (targeting 30-35% margins) provides a structural buffer and higher pricing power.
Q1 FY27 Revenue: ₹396 crQ1 FY27 PAT: ₹41 crEBITDA Margin: 20%Q1 Revenue vs TTM Revenue: 31.5%Patented Product Volume Growth: 37%
📅 Short termThe stock is likely to react positively to the sharp sequential turnaround and the doubling of net profit, signaling an end to the recent quarterly earnings volatility.
📈 Long termIf the company maintains its 13-14% growth target and continues increasing the share of patented products, it could lead to a structural re-rating of its valuation multiples.
⚠ Risk flags
- Irregular rainfall patterns affecting specific crop segments like vegetables and cotton
- High working capital pressure due to industry-standard 3-4 month credit cycles
- Competitive intensity in the non-patented segment
Key Highlights
PAT increased 104% YoY to ₹41 crore, representing a sharp recovery from the ₹37 crore loss in Q4 FY26.
EBITDA margins improved to 20% from 12% YoY, driven by gross margin expansion to 37%.
Patented products' contribution to branded sales rose to 64% from 45% in the previous year.
Volume of patented products sold increased by 37% YoY.
Company secured multiple new registrations including 9(3) TIM for Fluxametamide and Clethodim.
👀 What to Watch
Watch for the sustainability of 20%+ EBITDA margins through the remainder of the Kharif season and the impact of the 3-4 month credit cycle on working capital as sales volumes scale.
Best Agrolife Forfeits ₹37.50 Cr as Warrants Lapse; CapEx Budget Cut to ₹50 Cr
Best Agrolife Limited has reported a significant update regarding its December 2024 preferential issue of convertible warrants. The company has forfeited ₹37.50 crore following the lapse of warrants held by Excello Fin Lea Limited and Nova Global Opportunities Fund due to non-payment. Consequently, the planned allocation for Capital Expenditure has been revised downward from ₹70 crore to ₹50 crore, as these funds are no longer available for utilization.
Confidence: HIGH
What changedThe company has cancelled a portion of its planned fundraise and forfeited the initial deposit of ₹37.50 crore after investors failed to complete the warrant conversion.
Why it mattersThis reduces the total capital available for growth and expansion, specifically cutting the CapEx budget by nearly 28.5% from the original allocation.
Initial Amount Raised: ₹150 CrAmount Forfeited: ₹37.50 CrOriginal CapEx Allocation: ₹70 CrRevised CapEx Allocation: ₹50 CrDate of Fund Raising: 27-12-2024
📅 Short termThe news is likely to be viewed cautiously by the market as it indicates a shortfall in expected capital infusion and a reduction in planned investment.
📈 Long termLimited structural impact if the company can fund its requirements through internal accruals, but it highlights risks associated with preferential warrant issues to specific funds.
⚠ Risk flags
- Capital raising risk
- Investor default/non-payment
- Reduced budget for expansion
Key Highlights
₹37.50 crore forfeited by the company due to the lapse of convertible warrants
Capital Expenditure allocation reduced to ₹50 crore from the original ₹70 crore
Non-receipt of funds from specific investors: Excello Fin Lea Limited and Nova Global Opportunities Fund
Total initial fundraise amount via preferential issue was ₹150 crore dated 27-12-2024
Board formally took note of the warrant lapse and forfeiture in a meeting on June 27, 2026
👀 What to Watch
Investors should monitor if the ₹20 crore reduction in CapEx allocation delays any specific expansion projects or if the company seeks alternative funding sources to bridge the gap.
Q1 FY27 PAT doubles to ₹41 Cr; EBITDA margins expand to 20%
Best Agrolife reported a strong start to FY27 with PAT doubling to ₹41 Cr, a 104% YoY increase, despite a modest 4% revenue growth to ₹396 Cr. The performance was primarily driven by a significant expansion in EBITDA margins, which rose to 20% from 12% in the previous year, aided by a favorable product mix and price increases. Inventory levels saw a healthy reduction of 6% to ₹764 Cr, indicating better working capital management. However, the company remains under the cloud of ongoing income tax reassessments for multiple assessment years following a 2023 search operation.
Confidence: HIGH
What changedThe company has successfully pivoted from a loss-making quarter (₹37 Cr loss in Mar 2026) to a high-margin profitable quarter, validating its shift toward patented formulations.
Why it mattersThe sharp margin expansion suggests the company is gaining pricing power through its patented portfolio, which is critical for a small-cap player in the competitive agrochemical sector.
Q1 FY27 Revenue: ₹396 CrQ1 FY27 PAT: ₹41 CrEBITDA Margin: 20%Inventory: ₹764 CrQ1 PAT vs TTM PAT: 455%
📅 Short termThe stock is likely to react positively to the sharp recovery in profitability and margin expansion compared to the previous two loss-making quarters.
📈 Long termIf the company maintains 20%+ EBITDA margins through its patented product strategy, it could lead to a structural re-rating, though tax litigation remains a persistent overhang.
⚠ Risk flags
- Ongoing Income Tax reassessments for multiple years
- High inventory levels (nearly 2x quarterly revenue)
- Vulnerability to irregular rainfall patterns
Key Highlights
Net Profit (PAT) surged 104% YoY to ₹41 Cr in Q1 FY27 from ₹20 Cr in Q1 FY26.
EBITDA margins expanded by 800 basis points to 20% compared to 12% in the same quarter last year.
Gross margins improved significantly to 37% from 29% YoY, driven by patented products like Fluzam and Cubax Power Extra.
Inventory reduced by ₹48 Cr (6%) to ₹764 Cr as of June 30, 2026.
Revenue from operations grew 4% YoY to ₹396 Cr despite delayed monsoons affecting Kharif sowing.
👀 What to Watch
Monitor the sustainability of the 20% EBITDA margin in the peak Kharif season (Q2) and track the final resolution of Income Tax reassessment notices for AY 2017-18 to 2020-21.
Rs 37.5 Cr Forfeited as Warrant Holders Fail to Convert 23.43 Lakh Warrants
Best Agrolife Limited has forfeited Rs 37.5 crore following the non-exercise of conversion options for 23,43,750 warrants. These warrants were issued in December 2024 with an 18-month conversion window that expired on June 26, 2026. The forfeited amount represents the 25% initial subscription price paid by investors including Nahar Capital and Unico Global Opportunities Fund. While this provides a one-time capital boost to the company's reserves, the failure to convert suggests the market price remained unattractive relative to the adjusted conversion price of Rs 64.
Confidence: HIGH
What changedThe company has cancelled the 23,43,750 outstanding warrants and forfeited the 25% upfront payment, meaning no new equity shares will be issued to these holders.
Why it mattersFinancially, the company gains Rs 37.5 Cr in cash without any equity dilution, which is substantial given its TTM PAT of only Rs 9 Cr. However, it signals a lack of confidence from institutional warrant holders in the stock's near-term price potential.
Forfeited Amount: Rs 37.5 CrUnexercised Warrants: 23,43,750Adjusted Conversion Price: Rs 64Forfeiture vs TTM PAT: 416.6%Initial Subscription Paid: 25%
📅 Short termThe market may view the non-conversion as a negative signal regarding the company's valuation, though the immediate cash retention strengthens the balance sheet.
📈 Long termPrevents dilution of the equity base, which is beneficial for existing shareholders' EPS, but indicates challenges in raising capital at historical valuation benchmarks.
⚠ Risk flags
- Negative sentiment from institutional non-conversion
- Recent history of quarterly losses (e.g., -Rs 37 Cr in Mar 2026)
- High revenue volatility due to agro-climatic factors
Key Highlights
Forfeiture of Rs 37.5 crore representing 25% of the total issue price of the warrants
Total of 23,43,750 warrants remained unexercised by the June 26, 2026 deadline
Conversion price was adjusted from Rs 640 to Rs 64 per share following a stock subdivision
Major entities failing to convert include Nahar Capital and Financial Services Ltd and Unico Global Opportunities Fund
Forfeited amount of Rs 37.5 Cr is significantly higher than the TTM PAT of Rs 9 Cr
👀 What to Watch
Investors should monitor the company's upcoming quarterly results to see how the forfeited capital is utilized and whether operational margins improve after recent losses.
Rs 37.5 Cr Forfeited as 23.4 Lakh Warrants Lapse; Significant One-Time Gain for Best Agrolife
Best Agrolife has approved the forfeiture of Rs 37.50 Cr following the lapse of 23,43,750 convertible warrants. These warrants, originally allotted on December 27, 2024, expired on June 26, 2026, as the 17 warrant holders failed to exercise their conversion rights within the 18-month window. The forfeited amount represents the 25% initial subscription price paid by the holders. This non-refundable cash inflow is significant, representing over 4x the company's TTM PAT of Rs 9 Cr.
Confidence: HIGH
What changedA planned equity infusion has failed as warrant holders did not pay the remaining 75% exercise price, resulting in the company keeping the 25% deposit and the warrants being cancelled.
Why it mattersWhile the company gains Rs 37.5 Cr in cash without diluting equity, the failure to convert suggests that the warrant exercise price was likely higher than the prevailing market price, indicating a lack of immediate investor appetite at those levels.
Forfeited Amount: Rs 37.50 CrWarrants Lapsed: 23,43,750 unitsForfeited vs TTM PAT: 416.6%Forfeited vs Net Worth: 7.99%Exercise Period: 18 months
📅 Short termThe market may view the Rs 37.5 Cr cash windfall positively in the very short term, but the underlying reason (investors choosing not to convert) may cap upside.
📈 Long termThe company misses out on the remaining 75% of the capital (approx. Rs 112.5 Cr) it expected from these warrants, which could impact its long-term debt reduction or expansion timelines.
⚠ Risk flags
- Negative signal from 17 investors/entities refusing to convert warrants
- Potential shortfall in planned capital for growth
Key Highlights
Forfeiture of Rs 37,50,00,000 (Rs 37.50 Cr) representing 25% of the warrant issue price.
Lapse of 23,43,750 convertible warrants after the 18-month exercise period expired on June 26, 2026.
Total of 17 warrant holders, including Sunshare E-commerce Group (8.59 lakh warrants), failed to convert.
The forfeited amount is approximately 8% of the company's current Net Worth of Rs 469 Cr.
Avoidance of equity dilution from 23.4 lakh potential new shares.
👀 What to Watch
Investors should monitor the Q1 FY27 financial statements to see the accounting treatment of this Rs 37.5 Cr gain and assess if the company needs to seek alternative funding for its expansion plans.
Best Agrolife Promoters Confirm No New Share Encumbrances for FY 2025-26
Vimal Kumar, Promoter and Managing Director of Best Agrolife Limited, has filed a formal declaration under SEBI (SAST) Regulations for the financial year ending March 31, 2026. The disclosure confirms that the promoter group and persons acting in concert have not created any new direct or indirect encumbrances on their shares during the period. This annual filing is a mandatory compliance requirement to ensure transparency regarding promoter share pledges. It indicates that the promoter's leverage against company equity has not increased beyond previously disclosed levels.
Key Highlights
Declaration submitted under Regulation 31(4) and 31(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Promoter Vimal Kumar confirmed no new encumbrances were made during the 2025-2026 financial year.
The disclosure covers the entire Promoter and Promoter Group, including persons acting in concert.
The filing was submitted to both BSE and NSE on April 4, 2026, following the close of the financial year.
👀 What to Watch
Investors should take this as a sign of stability in the promoter's financial standing. No immediate action is required, but the lack of new pledges is a healthy indicator for long-term shareholders.
Best Agrolife FY26 Revenue Drops 31% to ₹1,257 Cr; Reports Q4 Net Loss of ₹37 Cr
Best Agrolife faced a difficult FY26 with consolidated revenue declining 31% YoY to ₹1,257 crore and PAT plunging 87% to ₹9 crore. The company reported a net loss of ₹37 crore in Q4 FY26, attributed to adverse weather, high channel inventory, and rising raw material costs due to geopolitical tensions. Management has focused on balance sheet health, successfully reducing inventory from ₹958 crore in FY24 to ₹651 crore. The company is now pivoting towards high-margin patented products and bio-stimulants to drive recovery in FY27.
Key Highlights
FY26 Revenue fell 31% YoY to ₹1,257 crore, while Q4 revenue dropped 43% to ₹156 crore.
Full-year PAT decreased to ₹9 crore from ₹70 crore in FY25, with EBITDA margins contracting to 8%.
Inventory levels significantly reduced to ₹651 crore as of March 2026, down from ₹958 crore in FY24.
Launched 3 patented products in FY26 (Bestman, Fetagen, Shot Down) with 4 more planned for FY27.
Implemented two rounds of price increases in April and May 2026 to mitigate rising input costs.
👀 What to Watch
Investors should exercise caution given the sharp decline in profitability and the Q4 loss, but monitor the execution of new patented product launches in FY27. The significant reduction in inventory is a positive sign of operational discipline, though recovery remains dependent on monsoon performance and global raw material stability.
Best Agrolife FY26 Revenue Drops 31% to ₹1,257 Cr; PAT Plummets to ₹9 Cr Amid Global Headwinds
Best Agrolife reported a challenging FY26 with revenue declining 31% YoY to ₹1,257 crore and PAT falling sharply to ₹9 crore from ₹70 crore in FY25. The company faced significant headwinds from rising raw material costs due to the Gulf conflict, leading to a strategic curtailment of sales in Q4 FY26 that impacted revenue by ₹50-70 crore. Despite the earnings hit, the company successfully reduced inventory to ₹651 crore and lowered OPEX by 15%. Management is pivoting towards high-margin patented products, which now contribute 41% to branded sales.
Key Highlights
Revenue from operations fell 31% YoY to ₹1,257 crore in FY26, with Q4 revenue dropping 43% to ₹156 crore.
Full-year PAT declined to ₹9 crore from ₹70 crore in FY25, while Q4 FY26 recorded a net loss of ₹37 crore.
Inventory levels were reduced significantly from ₹773 crore in FY25 to ₹651 crore as of March 31, 2026.
Patented products' contribution to branded sales increased to 41% in FY26, up from 30% in FY25.
Operating expenses (OPEX) were reduced by 15% YoY to ₹280 crore through geographic restructuring and cost optimization.
👀 What to Watch
Investors should monitor the effectiveness of the price hikes implemented in April and May 2026 to see if margins recover in Q1 FY27. While the shift toward patented products and lower inventory is structurally positive, the current earnings volatility suggests a cautious approach until profitability stabilizes.
Best Agrolife Recommends Rs 0.10 Final Dividend; Approves FY26 Audited Results
Best Agrolife Limited has recommended a final dividend of Rs 0.10 per equity share (10% of face value) for the financial year 2025-26. This announcement accompanied the approval of the company's audited standalone and consolidated financial results for the year ended March 31, 2026. The statutory auditors, Walker Chandiok & Co LLP, issued an unmodified opinion on the financial statements, ensuring reporting reliability. Additionally, the board appointed SHPH & Associates as the internal auditor for the 2026-27 fiscal year.
Key Highlights
Recommended a final dividend of Rs 0.10 per equity share of Rs 1 each for FY 2025-26
Approved audited standalone and consolidated financial results for the year ended March 31, 2026
Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion on the results
Appointed M/s SHPH & Associates as Internal Auditor for the financial year 2026-27
👀 What to Watch
Investors should review the detailed audited financial results to assess the company's growth trajectory beyond the nominal dividend payout. The unmodified audit opinion is a positive sign of financial transparency.
Best Agrolife Reports FY26 Net Profit of ₹20.50 Cr; Recommends 10% Dividend
Best Agrolife Limited reported a standalone net profit of ₹20.50 crore for the financial year ended March 31, 2026, on a revenue of ₹451.91 crore. For the fourth quarter (Q4 FY26), revenue stood at ₹100.12 crore, showing a decline from ₹111.96 crore in the year-ago period. The company has recommended a final dividend of ₹0.10 per share (10% of face value). A significant 'Emphasis of Matter' remains regarding ongoing Income Tax reassessments for multiple assessment years following a 2023 search and seizure operation.
Key Highlights
Standalone Net Profit for FY26 remained stable at ₹20.50 crore compared to the previous year.
Q4 FY26 revenue from operations declined to ₹100.12 crore from ₹111.96 crore in Q4 FY25.
Board recommended a final dividend of ₹0.10 (10%) per equity share of ₹1 each for FY 2025-26.
Auditors highlighted ongoing Income Tax reassessments for AY 2018-19 to 2021-22 with currently unascertainable financial impact.
Total standalone assets as of March 31, 2026, were valued at ₹901.72 crore.
👀 What to Watch
Investors should maintain a cautious stance due to the stagnant year-on-year growth and the regulatory overhang from the Income Tax department's reassessment proceedings. Monitor the final resolution of the tax matters as they could impact future cash flows.
Best Agrolife Q3 FY26: Revenue Falls 26% to ₹203 Cr; Net Loss Narrows to ₹12.7 Cr
Best Agrolife reported a challenging Q3 FY26 with revenue declining 26% YoY to ₹202.9 crore, primarily due to unseasonal rainfall and low pest pressure. Despite the revenue drop, the company managed to narrow its net loss to ₹12.7 crore from ₹24.2 crore in the previous year, aided by a 36% reduction in OPEX. The patented product portfolio remained resilient with only a 5% decline, whereas the non-patent segment saw a sharp 48% drop. Management highlighted the success of new launches, BestMan and Fetagen, which have already covered over 4 lakh acres each.
Key Highlights
Q3 FY26 revenue fell 26% YoY to ₹202.9 crore due to 49% higher rainfall in October disrupting the cropping cycle.
Net loss for the quarter narrowed to ₹12.7 crore compared to a loss of ₹24.2 crore in Q3 FY25.
EBITDA turned positive at ₹3.8 crore (1.9% margin) versus a loss of ₹5.8 crore in the year-ago period.
Non-patent portfolio revenue plunged 48% YoY, while the patented portfolio remained relatively stable with a 5% dip.
Operational expenses (OPEX) were aggressively reduced by 36% in Q3 through cost optimization and inventory control.
👀 What to Watch
Investors should monitor the company's ability to transition away from the volatile non-patent segment toward its higher-margin patented portfolio. While cost-cutting has narrowed losses, consistent revenue growth and rabi season recovery are essential for a trend reversal.
Best Agrolife Q3 FY26: Revenue Drops 26% to ₹203 Cr, EBITDA Turns Positive at ₹3.8 Cr
Best Agrolife reported a challenging Q3 FY26 with revenue declining 26% YoY to ₹202.9 crore, primarily due to unseasonal rainfall and lower pest incidence. Despite the revenue drop, the company turned EBITDA positive at ₹3.8 crore compared to a loss of ₹5.8 crore in the previous year's quarter. The net loss also narrowed to ₹12.7 crore from ₹24.2 crore YoY, aided by a 36% reduction in operating expenses. Management remains optimistic about future growth driven by patented products like BestMan and Fetagen, which saw strong initial adoption.
Key Highlights
Revenue from operations fell 25.97% YoY to ₹202.9 crore due to erratic rainfall and low pest pressure.
EBITDA improved to ₹3.8 crore (1.9% margin) from a loss of ₹5.8 crore in Q3 FY25.
Inventory levels were rationalized, reducing by 24% YoY to ₹589.47 crore as of Dec 31, 2025.
Patented products contributed 43% of brand sales in 9M FY26, up from 29% in the previous year.
Operating expenses (OPEX) were significantly reduced by 36% YoY during the quarter.
👀 What to Watch
Investors should monitor the company's ability to scale its high-margin patented portfolio and recover revenue growth in the upcoming seasons. While cost optimization is a positive sign, the impact of the pending Income Tax investigation remains a minor risk factor to watch.
Best Agrolife Q3 FY26: Revenue Drops 26% YoY to ₹202.9 Cr; Net Loss Narrows to ₹12.7 Cr
Best Agrolife reported a challenging Q3 FY26 with revenue declining 26% YoY to ₹202.9 crore, attributed to erratic rainfall and lower pest pressure. However, the company showed operational resilience as EBITDA turned positive at ₹3.8 crore compared to a loss of ₹5.8 crore in the previous year. The net loss for the quarter narrowed significantly to ₹12.7 crore from ₹24.2 crore. A key positive is the 23% YoY reduction in inventory to ₹589 crore and the increasing contribution of high-margin patented products, which now make up 43% of branded sales.
Key Highlights
Q3 FY26 revenue fell 26% YoY to ₹202.9 crore due to 49% above-average rainfall in October and lower pest incidence.
EBITDA improved to ₹3.8 crore (1.9% margin) from a loss of ₹5.8 crore in Q3 FY25, driven by a 36% reduction in OPEX.
Inventory levels were successfully reduced by 23% YoY, falling from ₹770 crore to ₹589 crore as of December 2025.
Patented products contribution to branded sales increased to 43% in 9M FY26, up from 29% in the previous year.
9M FY26 PAT stands at ₹46.1 crore with a margin of 4.2%, despite a 28.5% decline in 9M revenue to ₹1,101 crore.
👀 What to Watch
Investors should watch for a recovery in sales volumes as climatic conditions stabilize and the company shifts focus toward high-margin patented products. The significant reduction in inventory and OPEX suggests improved internal efficiencies despite the external revenue headwinds.
Best Agrolife Reports No Deviation in Utilization of ₹150 Cr Raised via Warrants
Best Agrolife Limited has submitted its statement of deviation for the quarter ended December 31, 2025, confirming no deviation in the utilization of funds raised through preferential warrants. The total issue size was adjusted to ₹150 crores from an original ₹200 crores due to lower subscription (23,43,750 warrants at ₹610 each). The company has utilized the initial 25% upfront payment of ₹37.5 crores as of June 2025. The board has also realigned the allocation, reducing Capital Expenditure to ₹50 crores and Working Capital to ₹90 crores to match the actual funds raised.
Key Highlights
Confirmed zero deviation or variation in the use of funds for the quarter ended December 31, 2025.
Total funds raised via preferential warrants stands at ₹150 crores, down from the initial target of ₹200 crores.
Upfront 25% proceeds amounting to ₹37.5 crores were fully utilized by June 2025.
Capital Expenditure allocation revised from ₹70 crores to ₹50 crores; Working Capital revised from ₹120 crores to ₹90 crores.
The warrants were issued at a price of ₹610 per unit.
👀 What to Watch
Investors should monitor the conversion of the remaining 75% of warrants, which will provide additional liquidity for the company's revised CapEx and working capital needs. The lack of deviation indicates disciplined adherence to the stated objects of the issue.
Best Agrolife Q3 FY26: Revenue Falls 26% YoY to ₹203 Cr; Losses Narrow to ₹12.7 Cr
Best Agrolife reported a challenging Q3 FY26 with revenue falling 25.9% YoY to ₹202.9 crore, primarily due to erratic rainfall and low pest incidence impacting demand. Despite the top-line hit, the company showed operational resilience as EBITDA turned positive at ₹3.8 crore compared to a loss of ₹5.8 crore in the previous year. The net loss for the quarter narrowed to ₹12.7 crore from ₹24.2 crore in Q3 FY25. For the nine-month period, PAT stands at ₹46.1 crore, a significant decline from ₹91.8 crore in 9M FY25, though inventory and OPEX levels have been successfully reduced.
Key Highlights
Q3 FY26 revenue decreased 25.9% YoY to ₹202.9 crore due to climatic factors and generic inventory pressure.
Net loss for the quarter narrowed to ₹12.7 crore from a loss of ₹24.2 crore in the corresponding quarter last year.
Inventory levels were rationalized by 24% YoY, reducing from ₹770 crore to ₹589.47 crore.
Patented products' contribution to brand sales increased significantly to 43% in 9M FY26 from 29% in 9M FY25.
Operational efficiency improved with Q3 OPEX (excluding finance and depreciation) reduced by 36% YoY.
👀 What to Watch
Investors should monitor the company's ability to recover revenue growth through its new patented product launches. While operational discipline and inventory reduction are positive, the sharp decline in 9M profitability suggests a cautious outlook until demand stabilizes.
Best Agrolife Allots 11.82 Crore Bonus Equity Shares in 1:2 Ratio
Best Agrolife Limited has successfully allotted 11,82,23,700 bonus equity shares to shareholders in a 1:2 ratio following board approval on January 19, 2026. This corporate action increases the company's paid-up equity share capital from Rs. 23.64 crore to Rs. 35.46 crore. The board has also reserved 1.17 crore bonus shares for outstanding warrant holders, to be issued upon full conversion. The new shares will rank pari-passu with existing equity and aim to improve stock liquidity.
Key Highlights
Allotment of 11,82,23,700 fully paid-up equity shares of Re. 1/- each
Bonus issue ratio of 1:2 (one new share for every two existing shares held)
Paid-up capital increased to Rs. 35,46,71,100 from Rs. 23,64,47,400
Reservation of 1,17,18,750 bonus shares for future conversion of outstanding warrants
Record date for eligibility was fixed as January 16, 2026
👀 What to Watch
Existing shareholders should see the bonus shares credited to their demat accounts shortly; no action is required as the market price has already adjusted for the 1:2 ratio.
Best Agrolife Receives In-Principal Approval for 12.99 Crore Bonus Shares
Best Agrolife Limited has successfully obtained in-principal approval from both the National Stock Exchange (NSE) and BSE Limited for its bonus share issuance. The company is set to issue 12,99,42,450 bonus equity shares with a face value of Rs. 1 each. The approvals were communicated via exchange letters dated December 31, 2025, and January 1, 2026. This procedural milestone brings the company closer to finalizing the bonus issue for its shareholders.
Key Highlights
Received in-principal approval for 12,99,42,450 bonus equity shares
Bonus shares carry a face value of Rs. 1 per share
Approvals obtained from both NSE (Jan 1, 2026) and BSE (Dec 31, 2025)
Compliance confirmed under Regulation 30 of SEBI (LODR) Regulations
👀 What to Watch
Investors should track the upcoming announcement of the record date to ensure eligibility for the bonus shares. Note that while share count increases, the stock price will adjust proportionally on the ex-bonus date.
Best Agrolife Sets Jan 16 as Record Date for 1:10 Stock Split and 1:2 Bonus Issue
Best Agrolife Limited has finalized January 16, 2026, as the record date for its upcoming stock split and bonus issue. The company will sub-divide each equity share of face value Rs. 10 into 10 shares of face value Re. 1. Additionally, shareholders will receive one bonus share for every two shares held post-split. This move is intended to increase liquidity and make the stock more accessible to retail investors.
Key Highlights
Record date for split and bonus eligibility is fixed for Friday, January 16, 2026
Stock split ratio of 1:10 will reduce face value from Rs. 10 to Re. 1 per share
Bonus issue ratio of 1:2 provides one additional share for every two shares held post-split
Corporate action follows the initial Board recommendation made on December 03, 2025
👀 What to Watch
Investors should be aware that the stock price will adjust downwards on the ex-date to reflect the split and bonus, while the number of shares in their portfolio will increase. No action is required for existing shareholders to receive the benefits as long as they hold the shares on the record date.
Best Agrolife Shareholders Approve Bonus Issue and Increase in Authorized Capital at EGM
Best Agrolife Limited conducted an Extraordinary General Meeting (EGM) on December 29, 2025, to obtain shareholder approval for key corporate actions. The meeting focused on two primary resolutions: the issuance of bonus shares and an increase in the company's authorized share capital. A total of 64 members attended the virtual meeting, and the voting results, including remote e-voting from December 26-28, will be finalized shortly. This move typically aims to improve stock liquidity and signals management's confidence in the company's long-term growth.
Key Highlights
Shareholders transacted the resolution for the issuance of Bonus Shares to existing members.
Proposal to increase Authorized Share Capital and alter the Memorandum of Association was presented.
The EGM was held on December 29, 2025, with 64 members participating via video conferencing.
Remote e-voting was available for three days prior to the meeting, ending on December 28, 2025.
Management addressed shareholder queries during the meeting before concluding at 1:40 P.M.
👀 What to Watch
Investors should look out for the official announcement of the bonus ratio and the record date to ensure eligibility for the bonus shares. The expansion of authorized capital suggests the company is preparing for future growth or further equity-based corporate actions.
